KI 0503Alternative Names: KI0503
Latest Information Update: 20 Aug 2015
At a glance
- Originator Kuhnil Pharmaceutical Company
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Joint disorders
Most Recent Events
- 20 Aug 2015 Phase-II development is ongoing in South Korea
- 01 Feb 2011 Phase-II clinical trials in Joint disorders in South Korea (unspecified route)